文献速递腹部CT

灌注CT预测不可切除晚期胃癌患者化疗治疗结局

Prediction of Treatment Outcome of Chemotherapy Using Perfusion Computed Tomography in Patients with Unresectable Advanced Gastric Cancer.
PubMed 文献 · Korean J Radiol · 2019-01-01

前瞻性纳入21例不可切除晚期胃癌患者,行灌注CT并接受姑息化疗,按RECIST 1.1评估疗效。应答组PS值51.0 mL/100 g/min显著高于非应答组23.4 mL/100 g/min(p=0.002),PS值预测应答的AUC为0.911,切点29.7 mL/100 g/min时敏感度100%、特异度80%。

要点

  • 灌注CT的PS值在化疗应答组显著高于非应答组(51.0 vs 23.4 mL/100 g/min,p=0.002)。
  • PS值预测化疗应答的AUC为0.911,切点29.7 mL/100 g/min时敏感度100%、特异度80%。
  • PS值>29.7 mL/100 g/min者1年生存率66.7%,显著高于PS值≤29.7者的33.3%(p=0.019)。

核心结论

  • 灌注CT获得的灌注参数数据对姑息化疗后的治疗结局具有预测价值,表现为应答组PS值显著高于非应答组。

研究设计与样本

  • 前瞻性纳入21例不可切除晚期胃癌患者,均行灌注CT并接受姑息化疗;按RECIST 1.1分为应答组(完全或部分缓解)与非应答组。

诊断标准与关键数值

  • PS值预测应答的AUC为0.911(p=0.004),切点29.7 mL/100 g/min时敏感度100%(6/6)、特异度80%(12/15)。

临床应用与阅片要点

  • 疗效评估采用RECIST 1.1,完全或部分缓解者归为应答组。
  • PS值在应答组为51.0 mL/100 g/min、非应答组为23.4 mL/100 g/min(p=0.002),其他灌注CT参数两组间无显著差异。
  • PS值>29.7 mL/100 g/min的9例患者1年生存率66.7%,PS值≤29.7 mL/100 g/min的12例患者为33.3%(p=0.019)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate whether data acquired from perfusion computed tomography (PCT) parameters can aid in the prediction of treatment outcome after palliative chemotherapy in patients with unresectable advanced gastric cancer (AGC).

MATERIALS AND METHODS: Twenty-one patients with unresectable AGCs, who underwent both PCT and palliative chemotherapy, were prospectively included. Treatment response was assessed according to Response Evaluation Criteria in Solid Tumors version 1.1 (i.e., patients who achieved complete or partial response were classified as responders). The relationship between tumor response and PCT parameters was evaluated using the Mann-Whitney test and receiver operating characteristic analysis. One-year survival was estimated using the Kaplan-Meier method.

RESULTS: After chemotherapy, six patients exhibited partial response and were allocated to the responder group while the remaining 15 patients were allocated to the non-responder group. Permeability surface (PS) value was shown to be significantly different between the responder and non-responder groups (51.0 mL/100 g/min vs. 23.4 mL/100 g/min, respectively; p = 0.002), whereas other PCT parameters did not demonstrate a significant difference. The area under the curve for prediction in responders was 0.911 (p = 0.004) for PS value, with a sensitivity of 100% (6/6) and specificity of 80% (12/15) at a cut-off value of 29.7 mL/100 g/min. One-year survival in nine patients with PS value > 29.7 mL/100 g/min was 66.7%, which was significantly higher than that in the 12 patients (33.3%) with PS value ≤ 29.7 mL/100 g/min (p = 0.019).

CONCLUSION: Perfusion parameter data acquired from PCT demonstrated predictive value for treatment outcome after palliative chemotherapy, reflected by the significantly higher PS value in the responder group compared with the non-responder group.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Lee DH, Kim SH, Lee SM, et al. Prediction of Treatment Outcome of Chemotherapy Using Perfusion Computed Tomography in Patients with Unresectable Advanced Gastric Cancer. Korean J Radiol. 2019. PMID: 30887741. doi:10.3348/kjr.2018.0306

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。